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ABSTRACT
Narrowing the search for the critical hTERT repressor sequence(s) has identified 
three regions on chromosome 3p (3p12-p21.1, 3p21.2 and 3p21.3-p22). However, the 
precise location and identity of the sequence(s) responsible for hTERT transcriptional 
repression remains elusive. In order to identify critical hTERT repressor sequences 
located within human chromosome 3p12-p22, we investigated hTERT transcriptional 
activity within 21NT microcell hybrid clones containing chromosome 3 fragments. 
Mapping of chromosome 3 structure in a single hTERT-repressed 21NT-#3fragment 
hybrid clone, revealed a 490kb region of deletion localised to 3p21.3 and encompassing 
the histone H3, lysine 36 (H3K36) trimethyltransferase enzyme SETD2; a putative 
tumour suppressor gene in breast cancer. Three additional genes, BAP1, PARP-3 and 
PBRM1, were also selected for further investigation based on their location within the 
3p21.1-p21.3 region, together with their documented role in the epigenetic regulation 
of target gene expression or hTERT regulation. All four genes (SETD2, BAP1, PARP-3 
and PBRM1) were found to be expressed at low levels in 21NT. Gene copy number 
variation (CNV) analysis of SETD2, BAP1, PARP-3 and PBRM1 within a panel of nine 
breast cancer cell lines demonstrated single copy number loss of all candidate genes 
within five (56%) cell lines (including 21NT cells). Stable, forced overexpression 
of BAP1, but not PARP2, SETD2 or PBRM1, within 21NT cells was associated with a 
significant reduction in hTERT expression levels relative to wild-type controls. We 
propose that at least two sequences exist on human chromosome 3p, that function 
to regulate hTERT transcription within human breast cancer cells.
INTRODUCTION
Cellular immortality is one of the ten hallmarks of 
human cancer and is an essential pre-requisite for malignant 
progression [1–3]. In contrast, normal human somatic cells 
proliferate for a limited number of population doublings 
before entering a permanent state of growth arrest known 
as replicative senescence [4, 5]. Telomeres are specialised 
nucleoprotein structures located at eukaryotic chromosome 
ends, that function to maintain the stability and integrity 
of chromosome structure, and play an important role in 
regulating cellular lifespan [6]. The reverse transcriptase 
ribonucleoprotein enzyme complex, telomerase, which is 
encoded by the hTERT gene, synthesizes telomeric repeat 
sequences at eukaryotic chromosome termini [7]. Over 90% 
of human tumours have been found to express telomerase, 
whereas the majority of normal human somatic cells do 
not [8]. This implies that activation of telomerase could be 
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responsible for the unlimited replicative potential of human 
tumour cells. Telomerase-positive human tumour cell lines 
have been found to contain up to 6 molecules of cytoplasmic 
hTERT mRNA, whereas telomerase-negative normal cells 
lack detectable levels [9]. Furthermore, intron-containing 
pre-spliced hTERT mRNA can only be detected within 
telomerase-positive cells. This suggests that telomerase 
expression is regulated primarily by the rate of hTERT 
transcription. Spontaneous immortalisation of normal human 
somatic cells has never been found to occur in vitro; however, 
ectopic expression of hTERT within normal primary human 
fibroblasts and epithelial cells can be sufficient to confer 
cellular immortality [10–12]. Furthermore, inhibition of 
hTERT expression within telomerase-positive human tumour 
cells is associated with telomere shortening and induction of 
cell death or senescence pathways in vitro and elimination 
of tumour formation in vivo [13–15]. It is therefore thought 
that de-repression of hTERT expression is a critical 
step for telomerase reactivation and subsequent cellular 
immortalisation during human carcinogenesis.
Transcription factors, hormones, as well as epigenetic 
mechanisms have been found to regulate hTERT expression 
within human cells [16]. However, the precise mechanisms 
that confer hTERT de-repression during carcinogenesis 
remain elusive. Whole somatic cell fusion of immortal 
tumour cell lines with normal human cells has been found 
to produce telomerase-repressed hybrids with a finite 
replicative capacity [17]. hTERT expression within human 
tumour cells therefore behaves as a recessive trait, which 
suggests that loss of critical repressor sequences may be 
responsible for hTERT activation. Evidence from human 
monochromosome transfer studies support this notion 
and demonstrate that hTERT repressor sequences exist on 
chromosomes 3, 4, 6, 7, 10 and 17 [reviewed by 17, 18].
We have shown previously that introduction of a 
normal, intact copy of human chromosome 3 into the 21NT 
primary breast cancer cell line by microcell-mediated 
monochromosome transfer (MMCT), is associated with 
strong repression of telomerase and hTERT transcription 
and induction of growth arrest within the majority of hybrid 
clones [9, 14]. Structural mapping of chromosome 3 within 
telomerase-positive revertent clones revealed two regions 
of deletion: 3p21.3-p22 and 3p12-p21.1, thought to harbour 
the putative telomerase repressor sequence(s). A subsequent 
study showed that the chromosome 3p-encoded telomerase 
repressor sequence(s) mediates its function by means 
of transcriptional silencing of hTERT, in part, through 
chromatin remodelling of two sites within intron 2 of the 
hTERT gene [19]. Our mapping data providing evidence 
suggesting that hTERT repressor sequences may be present 
within a 350kb region on 3p21.2 [18–19].
In this study, we narrowed the search for chromosome 
3p-encoded sequences responsible for conferring hTERT 
repression within 21NT cells by mapping the chromosome 
3 structure in a single hTERT-repressed 21NT microcell 
hybrid containing a chromosome 3 fragment. We identified 
a 490kb region, localised to 3p21.3, which encompasses 
the putative breast cancer tumour suppressor gene and 
H3K36 trimethyltransferase known as SETD2 [20, 21]. In 
addition to SETD2, a review of relevant literature identified 
a further three candidate telomerase repressor genes that (i) 
are located proximal to or within the 3p21.3-p22 region, (ii) 
have been previously implicated in breast cancer and (iii) 
have been shown to play a functional role in the epigenetic 
regulation of target gene transcription through chromatin 
remodelling and/or have been implicated in hTERT 
regulation within other cancer cell types. We report that 
stable, forced overexpression of BAP1 within 21NT cells is 
associated with a significant reduction in immature hTERT 
mRNA expression levels relative to wild-type controls. Our 
results suggest that at least two sequences on chromosome 
3p function to regulate hTERT transcription within human 
breast cancer cells.
RESULTS
Localization of a 490kb region on human 
chromosome 3p21.31 associated with repression 
of pre-spliced hTERT transcription in human 
21NT breast cancer cells
The initial aim of the study, was to narrow the 
search for sequences localised to human chromosome 
3p that function to repress hTERT transcription within 
21NT breast cancer cells. To achieve this, chromosome 
3 fragments generated by radiation exposure of A9-
Hytk3 human: mouse monochromosome hybrids, 
were introduced into PB1 (21NT-exohTERT) cells by 
microcell transfer. 30 individual PB1-#3fragment hybrid 
clones containing chromosome 3 fragments were picked 
and propagated as individual clones. The hybrids were 
mapped using polymorphic markers spanning the whole 
length of human chromosome 3 (data not shown). hTERT 
quantitation was also performed on all hybrid clones using 
real-time qPCR (data not shown). As shown in (Figure 1A), 
nine of the PB1-#3fragment hybrid clones generated, 
exhibited a greater than 55% reduction in pre-spliced 
hTERT mRNA relative to wild-type (PB1) controls. 
Genotyping revealed that these clones (CL1-9) contained 
the smallest fragments of chromosome 3 and still retained 
the ability to repress hTERT (the other clones contained 
much larger fragments which would make searching for 
the repressor much more difficult). Some of the clones 
however were unstable (CL1, CL2 and CL7) and did not 
grow beyond a few passages. Clone CL8 proved to be 
the most stable when continuously passaged, therefore 
it was selected for further analysis by transferring it 
back into the mouse A9 background. The chromosome 
3 fragment residing within clone 8 (CL8), which 
demonstrated a 77% reduction in hTERT mRNA levels 
relative to wild-type 21NT cells, was retro-transferred 
into mouse A9 fibroblasts by microcell transfer in order 
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to facilitate mapping using a series of non-informative 
polymorphic markers. Cytogenetic analysis was carried 
out on the retro-transferred mouse cell line (A9-clone 
8#3fragment hybrids) and revealed the presence of 
human chromosome material containing a single discreet 
region of chromosome 3 material (Figure 1B). Mapping 
of chromosome 3 structure within mouse A9-clone8#3 
fragment hybrids using a series of polymorphic marker 
sequences, showed that the chromosome 3 fragment 
consisted of discreet regions of short arm (3p23, p21 and 
p11) and long arm (3q12 and q26) material (Figure 1C). 
Notably, one A9-clone8#3 fragment hybrid (C9) showed 
loss of a 490kb sequence, which maps to the 3p21.3 
region. In our lab we have shown that when chromosomes 
are transferred into recipient cells using MMCT, a 
percentage of the resulting clones acquire spontaneous 
chromosomal deletions of specific regions [14]. Clones 
CL1-9 were shown to have the smallest chromosome 3 
fragments which repress hTERT. When clone PB1#3CL8 
was transferred back into the A9 fibroblast background, 
14 clones in total were picked. Most were identical to 
C4, however 2 clones were obtained with spontaneous 
deletions within the 47Mb region at 3p21. One of these 
clones was C9. We considered C4 to be the clone which 
caused hTERT repression. Frequent loss of this 47Mb 
region was observed previously within telomerase-
positive segregant 21NT-chromosome 3 hybrids [14, 
19]. For this reason, the 3p21.3 region was considered a 
strong candidate to harbour the putative hTERT repressor 
sequence. Out of all six annotated genes located within 
this 490kb region (Figure 1C), SETD2 has previously 
been shown to function as an epigenetic regulator of 
gene transcription through histone H3 lysine 36 (H3K36) 
trimethylation [22]. A putative tumour suppressive role 
of SETD2 in breast cancer was reported by Sarakbi 
et al. [20], which demonstrated that SETD2 mRNA levels 
within malignant breast cancer tissues are significantly 
lower than normal breast tissue samples. Similarly, 
Figure 1: Localisation of a 490kb region on human chromosome 3p that represses hTERT transcription within 21NT-
hTERT (PB1) breast cancer cells. (A) qRT-PCR analysis of pre-spliced hTERT expression levels (mean ± S.E n=3) within PB1-human 
chromosome 3 (PB1-#3fragment) hybrid clones, relative to wild-type PB1 cells. (B) FISH analysis of a single mouse A9-clone 8#3fragment 
hybrid generated by retro-transfer of the #3 fragment from clone 8 into mouse A9 cells. Representative DAPI-stained metaphase spreads of 
mouse A9-clone 8#3fragment clones, hybridised with, (i) TexasRed-labelled total human genomic paint and (ii) FITC-labelled chromosome 
3-specific painting probes. (C) Summary of chromosome 3 microsatellite sequence-tagged site (STS) analysis of two mouse A9-clone 8#3 
fragment hybrids (clones 4 and 9). A list of genes located within the 490kb region of deletion observed in clone 9 is indicated. (NRQ-
Normalised relative quantity) Open circle represents loss of the marker while filled circles retained the marker.
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SETD2 mRNA levels have been found to be significantly 
lower within tumour samples than matched adjacent non-
cancerous tissue (ANCT) samples from 25 breast cancer 
patients [21]. These findings, together with the results 
presented in the present study, prompted us to investigate 
the functional role of SETD2 in the regulation of hTERT 
transcription within 21NT cells.
Identification of three additional telomerase 
repressor candidate genes localised to human 
chromosome 3p21.1-21.3
Three additional candidate genes were selected for 
further investigation as potential telomerase repressors 
(see methods section for details). These were BRCA1 
associated protein-1 (BAP1), polybromo 1 (PBRM1) and 
poly(ADP) ribose polymerase 3 (PARP-3).
In order to carry out a preliminary analysis of the 
putative tumour suppressive role of SETD2, BAP1, PBRM1 
and PARP-3 within breast cancer cells, we carried out gene 
CNV analysis of all candidates within a panel of nine breast 
cancer cell lines relative to three normal HMEC cell strains 
(see Supplementary Table 1 for the origin of each cell line/
strain used). Over half (56%) of breast cancer cell lines, 
including 21NT cells, were found to have undergone single 
copy loss of all candidate genes, whereas 22% of cell lines 
had gained a single copy, and 22% had no change in gene 
copy number compared with normal HMECs (Figure 2A 
and 2B). The SV40-immortalised breast cell line MTSV 
and the HCC1143 breast carcinoma cell line were found 
to have undergone distinct copy number alterations within 
the PBRM1 locus compared with the other loci examined. 
These findings are consistent with Xia et al [23], where a 
homozygous deletion encompassing exons 12-17 of the 
PBRM1 locus within HCC1143 cells was identified. Due 
to the high frequency of gene copy number loss within 
breast cancer cells, our results provide additional evidence 
that SETD2, BAP1, PBRM1 and PARP-3 may function as 
tumour suppressors in breast cancer cells. However, the 
functional consequence of this ~5.5Mb single copy deletion 
on chromosome 3p21.1-3p21 within the majority of these 
breast cancer cell lines is unknown (Figure 2A and 2B). 
We next performed real-time qPCR on the breast cancer 
cell lines and normal breast tissues using primer sequences 
specific to the candidate genes SETD2, BAP1 PBRM1 
and PARP-3 (Figure 2Ci-2Civ). In all cases, the level of 
expression of the 4 candidate genes were higher in normal 
tissues (HMEC’s) and lower in our chosen breast cancer cell 
lines 21NT and 21MT. This suggests that these genes may 
have tumour suppressive/telomerase repressive activity in 
21NT and 21MT.
Chromosome 3p21.1-21.3 encoded sequences 
BAP1, but not SETD2 PARP-3 and PBRM1, 
repress hTERT transcription within 21NT cells
In order to investigate the functional role of SETD2, 
BAP1, PBRM1 and PARP-3 in regulating hTERT 
transcription, we examined the effect of forced, stable 
overexpression of candidate genes on pre-spliced hTERT 
Table 1: Sequences of the synthetic oligonucleotides used as primers for qRT-PCR and thermal cycling parameters
Gene Primer name Sequence (5’-3’) Primer/probe +thermal 
cycling parameters













BAP1 BAP1-F AGAAATACTCACCCAAGGAG Primers: 0.45μM
Step 1:
95ºC 30sec
Step 2: (40cycles) 95ºC 







*hTERT transcripts were amplified for 50 cycles.
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expression within 21NT breast cancer cells. Following 
positive selection and isolation of stable clones, candidate 
gene and hTERT expression levels were examined. As 
shown in (Figure 3A, 3B and 3D), overexpression of 
PARP-3 and BAP1, but not PBRM1, within 21NT cells was 
associated with a significant reduction in hTERT expression 
levels when compared with wild-type 21NT cells. However, 
for PARP-3 (and to a lesser extent BAP1) transfection with 
the empty vector control also decreased hTERT expression.
Stable 21NT-SETD2 clones were found to exhibit 
a 1.7-fold average increase in SETD2 expression levels 
relative to untreated controls, which did not reach 
statistical significance. Therefore, the effect of increased 
SETD2 expression on hTERT transcriptional activity 
was unclear. In order to investigate this further, the effect 
of transient, high-level SETD2 expression on hTERT 
transcription over the course of six consecutive days 
was examined. For all time points, increased SETD2 
expression was found to be associated with increased 
hTERT expression levels relative to untreated controls 
(Figure 3Ciii and 3Civ). Despite empty vector controls 
also exhibiting a substantial increase in hTERT expression 
levels at 48, 120 and 144 hours post-transfection, it is clear 
that increased SETD2 expression was not associated with 
repression of hTERT transcription.
DISCUSSION
Over 90% of human breast carcinomas and up to 
75% of ductal carcinoma in situ (DCIS) lesions exhibit 
detectable levels of telomerase activity, whereas atypical 
ductal hyperplasia (ADH) and normal breast tissues do 
not [24–25]. Thus, telomerase reactivation is an early 
event during breast carcinogenesis that may promote 
tumour progression. A significant positive correlation 
between hTERT mRNA levels and telomerase activity 
Figure 2:The genomic positions and gene copy numbers of SETD2, PARP3, BAP1 and PBRM1 within a panel of 
breast cancer cell lines and normal human mammary epithelial cell (HMEC) strains. (A) Graphical representation of the 
approximate positions of candidate genes within the 3p21.1-p21.3 region of human chromosome 3. Genomic coordinates of all candidate 
genes were obtained from the National Centre of Biotechnology Information (NCBI) database. (B) Candidate gene copy number (CN) 
variation analysis of HMEC strains and a panel of nine breast cancer cell lines. (C) Real-time qPCR mRNA expression analysis for SETD2, 
PBRM1, BAP1 and PARP-3 in breast cancer cell lines and normal breast cells (HMEC’s).
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within human breast carcinomas has also been reported, 
which supports the notion that hTERT is the critical rate-
limiting component of telomerase enzyme activity [26]. 
Independent studies demonstrate a relationship between 
telomerase activity and breast tumour stage, nodal 
metastases and decreased disease-free survival [27–28]. To 
date, the key molecular mechanism(s) underlying hTERT 
transcriptional de-repression and telomerase reactivation 
during human breast carcinogenesis remain elusive.
Our group has demonstrated previously that 
introduction of a normal intact copy of human 
chromosome 3 into the primary breast carcinoma cell line 
21NT is associated with strong repression of telomerase 
and hTERT transcription and induction of cell growth 
arrest within the majority of hybrids [14, 19]. We also 
identified three candidate regions within 3p12-p22 that 
were thought to harbour the critical hTERT repressor 
sequence(s) [14, 19]. In the present study, radiation-
induced chromosome 3 fragments were transferred into 
21NT breast cancer cells by MMCT and a single fragment 
that was associated withhTERT transcriptional repression 
was identified. Following MMCT-mediated retro-transfer 
of this fragment into mouse A9 fibroblast cells, sequence-
tagged-site (STS) mapping of hybrid clones demonstrated 
that it was a chimeric fragment. It contained regions of 
chromosome 3 short and long-arm material including a 
490kb sequence located within the 3p21.3-p22 region, 
which was implicated in hTERT regulation by our group 
previously [14, 19]. In addition, studies have shown 
that the 3p21-p22 region is a frequent site of loss of 
heterozygosity (LOH) in breast cancer, indicating the 
presence of important tumour suppressor genes [29–30]. 
In support of this, the results presented in the present 
study demonstrated that 56% of breast cancer cell lines 
Figure 3: The effect of forced, stable overexpression of PARP-3, BAP1, SETD2 and PBRM1 on hTERT transcription 
within 21NT breast cancer cells. qRT-PCR analysis of average (Ai) PARP-3, (Bi) BAP1, (Ci) SETD2 and (Di) PBRM1 expression 
levels (mean ± S.E n=3) and (Aii, Bii, Cii, and Dii) pre-spliced hTERT expression levels (mean ± S.E n=3) across five independent stable 
21NT-candidate gene transfection clones and five independent stable 21NT-empty vector (EV) clones relative to parental 21NT cells 
(*p<0.05). Figure 3C shows (iii) SETD2 and (iv) hTERT expression levels (mean ± SD) within 21NT cells 48-144 hours following transient 
transfection of 21NT cells with pCMVNeo (EV) and pCMVNeo-SETD2 vector constructs, expressed relative to untreated 21NT cells. 
(NRQ-Normalised Relative Quantity).
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had undergone single copy number loss of four candidate 
hTERT-repressor genes (SETD2, BAP1, PBRM1 and 
PARP-3) spanning a 5.5 Mb region within 3p21.1-p21.3, 
which adds to the body of evidence that these genes play 
an important tumour suppressive role in breast cancer 
cells [20, 21, 26–30]. In addition, we have demonstrated 
that SETD2, BAP1, PBRM1 and PARP-3 are all down-
regulated in the breast cancer cell line 21NT when 
compared to normal cells (HMEC), making them prime 
targets for tumour suppression / telomerase repression in 
breast cancer.
In the present study, overexpression of BAP1, but 
not PARP3, PBRM1 or SETD2, was associated with 
significant (but not complete) repression of hTERT 
transcription within 21NT breast cancer cells. This 
suggests that at least two sequences may function, either 
independently or collectively, to confer hTERT repression 
in human breast cancer cells. Primary breast tumours have 
been found to undergo discontinuous allele loss of multiple 
regions of chromosome 3p [29]. Reverse selection of 
21NT-chromosome 3 hybrids that had lost the introduced 
chromosome 3 copy by ganciclovir (GCV) selection 
by our group previously [19], was associated with the 
restoration of an ‘open’ chromatin conformation around 
intron 2 of hTERT, but not associated with consistent 
re-activation of hTERT expression when compared to 
parental 21NT cells. Despite ensuring the absence of 
residual, exogenous chromosome 3p14.1-21.2 material 
within the majority of revertant clones, the presence of 
another repressor sequence outside of this region (perhaps 
within 3p21.2-p22) may have been responsible for the 
sustained repression of hTERT transcription. Therefore, 
it is possible that one chromosome 3p-encoded sequence 
functions to regulate the chromatin conformation around 
intron 2 of hTERT, while another sequence(s) may 
function to prevent binding of transcriptional activators of 
hTERT within or around this region.
In support of the notion that multiple hTERT 
repressor sequences exist on human chromosome 3p, 
whole somatic cell fusion of 21NT cells with two renal 
cell carcinoma cell lines (RCC23 and KC12), which are 
also known to confer hTERT repression when a normal 
chromosome 3 copy is introduced into these cell lines by 
MMCT, produces telomerase-negative hybrids [31–33]. A 
recent study has also reported that two functionally distinct 
hTERT regulatory sequences exist on human chromosome 
3p within human renal cell carcinoma and oral squamous 
cell carcinoma cells [34].
In conclusion, the results from the present study 
provide evidence to suggest that BAP1 and possibly 
PARP-3 repress hTERT transcription within breast 
cancer cells, which supports the hypothesis that multiple 
sequences on human chromosome 3p may be responsible 
for regulating hTERT transcription. Despite efforts to 
achieve positional cloning of critical hTERT repressor 
sequences in different cancers, the key molecular players 
and mechanisms by which they function to repress 
hTERT transcription remain unclear. Further investigation 
involving high resolution transcriptome profiling and next 
generation sequencing (NGS) of hTERT-repressed and 
segregant hTERT-positive 21NT-chromosome 3 hybrids 




The mouse (A9) human chromosome 3 hybrid 
donor cell line A9-Hytk3 [35], carrying a selectable 
fusion gene marker, Hytk (Hy, bacterial hygromycin 
phosphotransferase; tk, herpes simplex virus thymidine 
kinase) tagged on the human chromosome 3 copy, was 
maintained in Dulbecco’s modified Eagle medium 
(DMEM) containing 10% foetal bovine serum (FBS; 
Thermo Fisher Scientific, Inc., Waltham, MA, USA) 
and 400 U/ml hygromycin B (Calbiochem Corp., San 
Diego, CA, USA). All other cell lines were grown and 
maintained as described previously [36]. The 21NT 
cell line is a primary tumour line and is considered to 
be an early stage in breast cancer progression [37, 38]. 
21NT-exohTERT (21NT cells stably overexpressing 
exogenous hTERT and referred to as PB1 from herein) 
were maintained in the same culture conditions as 21NT 
cells [23]. Our group’s previous publications [9, 19] have 
shown that when chromosome 3 was transferred into the 
cell line 21NT, down-regulation of hTERT/telomerase 
and senescence occurs within ~3-4 weeks. Therefore, 
we have a small window in which to collect sufficient 
cells to perform downstream molecular analysis. To 
overcome this issue, we transfected the 21NT cell line 
with a plasmid expression vector (PCI-neo, Promega) 
containing the hTERT cDNA and picked clones (called 
PB1) which stably expressed exogenous hTERT using the 
CMV promoter. These PB1 cells express high levels of 
exogenous hTERT and do not go into senescence when 
intact whole human chromosome 3 is transferred into 
them [9, 19]. By expressing exogenous hTERT we are 
then able to study the repression of endogenous hTERT 
through transfection of human chromosome 3 and identify 
gene(s) responsible for the repression &/or de-repression 
of endogenous hTERT.
Generation of chromosome 3 fragments and 
microcell-mediated monochromosome transfer 
(MMCT)
Microcell-mediated transfer of chromosome 3 
fragments into 21NT or PB1 cells was carried out as 
described previously [14]. Fragmentation of chromosome 
3 was achieved by exposing microcells containing 
monochromosome 3 to 25-50 Gy of γ-radiation prior to 
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MMCT. Following microcell-fusion, PB1-chromosome 3 
fragment hybrids were selected in medium supplemented 
with 400 U/ml hygromycin B. Retro-transfer of 
chromosome 3 fragments from PB1 hybrid clones into 
mouse A9 fibroblasts was conducted using the standard 
MMCT procedure described previously [14].
Quantification of transcripts by quantitative 
real-time PCR (qRT-PCR)
Extraction of RNA from cell lines/strains was 
carried out using peqGOLD TriFast reagent (Peqlab; 
VWR International, Radnor, PA, USA) according to the 
manufacturer’s instructions. Removal of contaminating 
DNA from RNA extracts was achieved using the 
Deoxyribonuclease I (DNAse I), amplification grade 
enzyme (Invitrogen; Thermo Fisher Scientific, Inc.). 
Reverse transcription of 1 μg RNA into first-strand cDNA 
was carried out using the High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems; Thermo Fisher 
Scientific, Inc.). The primer sequences and thermal cycling 
parameters used to quantify hTERT, GAPDH, SETD2, 
BAP1, PBRM1 and PARP-3 transcripts are listed in Table 
1. qPCR was performed using iTaq™ Universal SYBR® 
Green Supermix or Universal Probes Supermix (BioRad, 
Hercules, CA, USA) as described previously [36].
Cytogenetic analysis of hybrids by fluorescence 
in situ hybridization (FISH)
FISH analysis was carried out as described 
previously [14]. A9 chromosome 3 fragment hybrids 
were hybridised with a total human DNA paint labelled 
with TexasRed, and a chromosome 3-specific green 
paint labelled with FITC (MetaSystems, Altlussheim, 
Germany).
DNA extraction
Extraction of genomic DNA from cell lines and 
strains was achieved using the Wizard® Genomic DNA 
Purification Kit (Promega, Madison, WI, USA) according 
to the manufacturer’s instructions.
Sequence-tagged microsatellite mapping
PB1-chromosome 3 fragment hybrids were initially 
mapped as previously described [14]. Polymorphic 
markers spanning the whole length of human chromosome 
3 were selected from the NCBI database to carry out 
microsatellite mapping. Due to the high level of non-
informative markers in our region of interest (3p21.3-p22 
and 3p12-p21.1), PB1 chromosome 3 hybrid clones were 
retro-transferred back into the A9 mouse background for 
fine-structure mapping using STS markers and standard 
PCR procedures.
Gene copy number variation (CNV) analysis
CNV analysis was performed as described 
previously [39]. SETD2, BAP1, PARP-3 and PBRM1 
CNV analysis was performed using pre-designed Taqman® 
Copy Number Assay primers (Applied Biosystems; 
Thermo Fisher Scientific, Inc.; assay reference numbers, 
Hs01027663_cn, Hs02357352_cn, Hs01428519_cn and 
Hs06624309_cn, respectively). Assays were run in a 
duplex reaction with RNAseP Taqman® Reference Assay 
(reference number: 4403326) to normalise target gene 
copy number.
Identification of three additional candidate 
hTERT repressor sequences localised to human 
chromosome 3p21.1-3p21.3: PARP-3, BAP1 and 
PBRM1
Previous studies have identified three putative 
regions on chromosome 3p that may harbour hTERT 
repressor sequences within breast cancer cells, including 
3p21.3-p22, 3p12-p21.1 and 3p21.2 [14, 19]. Therefore, 
a review of relevant literature was conducted in order to 
identify additional candidate hTERT repressor sequences 
that are (i) located within the 3p12-p22 region, (ii) have 
been implicated in breast cancer and (iii) have been shown 
to serve a functional role in the epigenetic regulation of 
target gene transcription through chromatin remodelling 
and/or have been implicated in hTERT transcription 
regulation. Three interesting candidate genes, including 
BRCA1 associated protein-1 (BAP1), polybromo 1 
(PBRM1) and poly(ADP) ribose polymerase 3 (PARP-3) 
were selected for further investigation.
BAP1 has been found to interact directly with 
known repressors of hTERT transcription, including 
BRCA1 and E2F-1 [40–43]. Additionally, co-transfection 
of BAP1 and its interacting partner BRCA1, is associated 
with a significant reduction in the clonogenic survival of 
MCF7 breast cancer cells [41]. Loss of heterozygosity 
(LOH) of the PBRM1 genomic locus and truncating 
mutations within the bromodomains (BD) of PBRM1 
has been identified in breast cancer cell lines [23]. 
Transient overexpression of PARP-3 within the A549 lung 
adenocarcinoma cell line was associated with a significant 
reduction in telomerase activity at 48 and 96 h following 
transfection compared with empty vector controls [44].
Investigating the effect of SETD2, BAP1, 
PARP-3 and PBRM1 overexpression on hTERT 
transcription within 21NT cells
The plasmid vectors pCMV6AC-BAP1 (OriGene 
Technologies Inc., Rockville, MD, USA), pBABEpuro-
BAF180/PBRM1 [26], pCMVNeo-PARP-3 and 
associated empty vector controls were used to generate 
stable BAP1, PBRM1 and PARP-3, 21NT transfection 
Oncotarget61898www.impactjournals.com/oncotarget
clones, respectively. SETD2 and PARP-3 cDNA was 
cloned into pCMVNeo vectors (OriGene Technologies, 
Inc.) and re-sequenced to confirm that the cDNAs 
were in the correct orientation. Overexpression of 
SETD2, BAP1, PARP-3 and PBRM1 within the 21NT 
cell line was achieved using the TransIT®-BrCa 
Transfection Reagent (Mirus Bio, Madison, WI, USA) 
according to manufacturer’s instructions. A minimum 
of 5 stable 21NT-target gene and 5 stable 21NT-empty 
vector control clones were then isolated at random 
and propagated as individual cell lines. Transient 
overexpression of SETD2 within 21NT cells was 
achieved by harvesting cells at 24 h intervals, starting 
from 48 h following transfection with pCMVNeo or 
pCMVNeo-SETD2 plasmids. The mRNA expression 
levels of SETD2, BAP1, PARP-3, PBRM1 and hTERT 
were determined as described above.
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